2 transcripts
SLRN
Earnings call transcript
NASDAQ
2024 Q2
13 Aug 24
, our early anti-c-KIT program. Data from healthy volunteers demonstrated molecular activity, but we have made the decision to deprioritize
SLRN
Earnings call transcript
NASDAQ
2023 Q2
14 Aug 23
-of-concept trial of SLRN-517 is ongoing and will include healthy volunteers and chronic urticaria patients. We expect top-line results in the second half
- Prev
- 1
- Next